Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682850 | 0.88 | PTK2 (0.55) | PTK2MAPK14POLQMAP4K4ATR | |
| SCHEMBL1682860 | 0.85 | PTK2 (0.57) | PTK2L3MBTL1MAP4K4NPC1RAB9A | |
| SCHEMBL1682792 | 0.80 | PTK2 (0.56) | PTK2 | |
| SCHEMBL1682796 | 0.73 | PTK2 (0.50) | PTK2MAP4K4NPC1RAB9ASYK | |
| SCHEMBL13519120 | 0.72 | PTK2 (0.41) | PTK2ATR | |
| SCHEMBL12398419 | 0.72 | PTK2 (0.45) | PTK2SYK | |
| SCHEMBL1674327 | 0.72 | PTK2 (0.44) | PTK2NPC1RAB9ASYK | |
| SCHEMBL1682852 | 0.71 | PTK2 (0.60) | PTK2MAP4K4ATR | |
| SCHEMBL19102523 | 0.71 | SYK (0.50) | L3MBTL1NPC1RAB9ASYK | |
| SCHEMBL1682825 | 0.70 | PTK2 (0.52) | PTK2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| EP-2491043-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KIST Korea Institute of Science and Technology (KR) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, TK1, DTYMK | PTK2 292/4885L3MBTL1 3112/4885MAPK14 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.